Cargando…
Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder
BACKGROUND: Several studies have reported the efficacy and safety of rituximab (RTX) and mycophenolate mofetil (MMF) in neuromyelitis optica spectrum disorder (NMOSD). This study aimed to evaluate the efficacy and safety of long-term use of low-dose RTX and MMF in Chinese patients with NMOSD. METHOD...
Autores principales: | Lin, Jie, Xue, Binbin, Li, Jia, Zhu, Ruofan, Pan, Juyuan, Chen, Zhibo, Zhang, Xu, Li, Xiang, Xia, Junhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120916/ https://www.ncbi.nlm.nih.gov/pubmed/35599732 http://dx.doi.org/10.3389/fneur.2022.891064 |
Ejemplares similares
-
Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study
por: Jiao, Yujuan, et al.
Publicado: (2018) -
Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis
por: Aungsumart, Saharat, et al.
Publicado: (2020) -
Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China
por: Huang, Qiao, et al.
Publicado: (2018) -
Retrospective Observation of Low-Dose Rituximab Treatment in Chinese Patients With Neuromyelitis Optica Spectrum Disorders in a Real-World Setting
por: Xiao, Haibing, et al.
Publicado: (2020) -
Efficacy of Low-Dose Rituximab on Neuromyelitis Optica-Associated Optic Neuritis
por: Zhao, Shuo, et al.
Publicado: (2021)